Medically Supervised Programs
GLP-1 Program Options
and Provider Support
Compare our GLP-1 program options and learn how provider support fits into care. Programs start at $149/month; your provider will determine whether semaglutide or tirzepatide is appropriate.
What Is GLP-1 Therapy?
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications that mimic your body's natural appetite-regulating hormones. They reduce hunger, slow digestion, and quiet the constant mental chatter about food — often called "food noise."
These medications are not stimulants, not crash diets, and not appetite suppressants in the traditional sense. They work with your brain's own signaling system to make sustainable, lower-calorie eating feel natural rather than like deprivation.
At Sarasota Trim Clinic, GLP-1 programs are supervised by a licensed provider who tailors dosing to your health profile and monitors your progress every step of the way. Medication ships from a U.S.-based licensed pharmacy in 1–2 days.
How GLP-1 Quiets Food Noise
GLP-1 medications work in the brain's appetite center — specifically the hypothalamus — to reduce the persistent thoughts about food that make dieting feel impossible. Patients commonly report that cravings 'quiet down' within the first few weeks.
What to Expect at Your Consultation
Your provider reviews your health history, current medications, and weight loss goals. Most patients can begin their program the same week. Dose escalation is gradual — typically starting low and increasing monthly to minimize side effects.
Delivery and Ongoing Support
Your medication ships from a U.S.-based licensed pharmacy in 1–2 business days — always free. Your provider conducts regular follow-ups to adjust dosing, answer questions, and ensure you're progressing safely.
Safety and Monitoring
GLP-1 medications have been studied extensively and have strong clinical safety profiles. Your provider will discuss your full health history before prescribing. Patients with certain thyroid or pancreatic conditions may not be appropriate candidates.
Semaglutide vs. Tirzepatide — What's the Difference?
Both are GLP-1 medications. Both are highly effective. Your provider will help determine which is more appropriate for your health profile and goals.
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Receptor Targets | GLP-1 only | GLP-1 + GIP (dual-action) |
| Brand Names | Wegovy, Ozempic | Zepbound, Mounjaro |
| Administration | Weekly injection | Weekly injection |
| Avg. Weight Loss (trials) | ~15% body weight | ~20–22% body weight |
| FDA-Approved for Weight Loss | Yes (Wegovy) | Yes (Zepbound) |
| Appetite Reduction | Significant | Significant + GIP synergy |
| Right For | Most adults; first-line option | Patients seeking dual-pathway approach |
Weight loss averages from clinical trials. Individual results vary significantly. Your provider will help set realistic expectations based on your specific situation.
Side Effects — What You Should Know
We believe in full transparency about what to expect. Most side effects are manageable, especially with proper dose titration.
Nausea
Most common early, usually fades
Mild bloating / fullness
Common during dose escalation
Constipation
Common; manageable with diet
Decreased appetite
Expected — the mechanism of action
Fatigue (early)
Typically resolves in first weeks
Pancreatitis
Rare; requires immediate medical attention
RareThyroid concerns (MTC)
Rare; discuss family history with provider
RareImportant: This information is for general educational purposes only and does not constitute medical advice. Always discuss your full health history, current medications, and any concerns with your provider before and during treatment. If you experience severe or unusual symptoms, contact your provider immediately.
Want to Learn More Before Deciding?
Visit our patient library for honest, clear, jargon-free education on GLP-1 medications, what to expect, and how to evaluate whether this is right for you. Free — no login required.
MEDICAL SOURCES & FURTHER READING
These sources address the topics identified below. They provide general education, not individualized medical advice, a clinic endorsement or a prediction of your results. Prescription treatment requires evaluation by a licensed provider; eligibility, medication and dosing depend on individual circumstances.
NIH — National Institute of Diabetes and Digestive and Kidney Diseases
Prescription Medications to Treat Overweight & ObesityWeight-management medication eligibility, appetite, lifestyle support and individualized treatment decisions.
Mayo Clinic
Prescription weight-loss drugsPotential benefits, side effects, eligibility and the role of ongoing professional care.
Cleveland Clinic
GLP-1 AgonistsGLP-1 mechanisms, gastrointestinal effects, risks and when to contact a healthcare provider.
U.S. Food and Drug Administration
Wegovy prescribing information and Medication Guide (PDF)Semaglutide indications, mechanism, contraindications, thyroid warning, pancreatitis, pregnancy and adverse reactions; this label does not apply to compounded products.
U.S. Food and Drug Administration
Zepbound prescribing information and Medication Guide (PDF)Tirzepatide indications, dual GIP/GLP-1 mechanism, contraindications and adverse reactions; this label does not apply to compounded products.
U.S. Food and Drug Administration
FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight LossLack of FDA approval for compounded drugs, dosing errors, quality concerns and limits on compounding.
RESEARCH & REFERENCES
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P. H. Wilding, Rachel L. Batterham, Salvatore Calanna, et al.; STEP 1 Study Group · New England Journal of Medicine · 2021
Research published in the New England Journal of Medicine reported greater mean weight reduction with semaglutide plus lifestyle intervention than with placebo in the studied population. This was not a study of Sarasota Trim Clinic or compounded medication, and individual results vary.
- Tirzepatide Once Weekly for the Treatment of Obesity
Ania M. Jastreboff, Louis J. Aronne, Nadia N. Ahmad, et al.; SURMOUNT-1 Investigators · New England Journal of Medicine · 2022
Research published in the New England Journal of Medicine reported weight reduction across the tirzepatide groups during a 72-week trial with lifestyle intervention. Results depended on the trial regimen and population, do not establish compounded-product equivalence, and are not a clinic outcome or a guarantee.